<DOC>
	<DOCNO>NCT00976456</DOCNO>
	<brief_summary>Multi-center , open , randomize ( parallel ) comparative phase III . Eligible patient receive bevacizumab + chemotherapy minimum 4 cycle follow bevacizumab ( + pemetrexed , appropriate ) maintenance therapy disease progression . Arm A : Bevacizumab + pemetrexed Arm B : Bevacizumab + pemetrexed + carboplatin</brief_summary>
	<brief_title>Efficacy Study Avastin® With Pemetrexed +/- Carboplatin Treat Elderly Patients With Non-small Cell Lung Cancer</brief_title>
	<detailed_description>Primary : - Proof non-inferior efficacy monochemotherapy regimen pemetrexed plus bevacizumab versus combination chemotherapy regimen pemetrexed-carboplatin plus bevacizumab elderly patient ( &gt; 65 year ) first-line treatment advance metastatic recurrent non-squamous NSCLC progression free survival Secondary : - To assess efficacy bevacizumab measure overall response rate overall survival . - To assess safety bevacizumab combination pemetrexed pemetrexed carboplatin . - To assess quality life EORTC questionnaire QLQ-C30 lung cancer module LC-13 - To assess activity daily life ( iADL ) relation ECOG performance status prior study treatment - To assess patient ` outcome treatment delivery relation Charlson comorbidity score Simplified Comorbidity Score</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Stage IIIb IV NSCLC , exclude squamous cell NSCLC Age ≥ 65 year ECOG 02 Mixed , nonsmall cell small cell tumour mix adenosquamous carcinoma predominant squamous component History haemoptysis Evidence tumour invade major blood vessel image Radiotherapy within 28 day prior enrolment Patients unable interrupt aspirin nonsteroidal antiinflammatory agent , aspirin dose ≤ 1.3 gram per day , 5day period ( 8day period longacting agent , piroxicam ) Current recent ( within 10 day first dose bevacizumab ) use fulldose oral parenteral anticoagulant thrombolytic agent therapeutic purpose . Prophylactic use anticoagulant allow Clinically significant ( i.e . active ) cardiovascular disease example CVA ( ≤6 month enrolment ) , myocardial infarction ( ≤6 month enrolment ) , unstable angina , CHF NYHA Class ≥II , serious cardiac arrhythmia require medication study might interfere regularity study treatment , control medication Nonhealing wound , active peptic ulcer bone fracture History abdominal fistula , gastrointestinal perforation intraabdominal abscess within 6 month enrolment</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>lung cancer</keyword>
	<keyword>NSCLC</keyword>
	<keyword>elderly</keyword>
	<keyword>non-squamous</keyword>
	<keyword>Elderly patient least 65 year old</keyword>
	<keyword>first line therapy</keyword>
	<keyword>non-squamous non-small cell lung cancer stage IIIb IV</keyword>
</DOC>